BELITE BIO INC - AMER

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

22 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

11 мар 2024 22:28:39 Источник Nasdaq GlobeNewswire

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

11 мар 2024 21:27:47 Источник Nasdaq GlobeNewswire

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

06 мар 2024 08:00:01 Источник Nasdaq GlobeNewswire

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

04 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

07 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

30 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio to Participate in the BTIG Ophthalmology Day

20 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

13 ноя 2023 20:15:47 Источник Nasdaq GlobeNewswire

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

07 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

06 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

27 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

08 авг 2023 22:17:28 Источник Nasdaq GlobeNewswire

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

04 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

27 июл 2023 17:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

30 май 2023 20:49:26 Источник Nasdaq GlobeNewswire

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

30 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

10 май 2023 19:58:59 Источник Nasdaq GlobeNewswire

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

10 май 2023 15:33:22 Источник Nasdaq GlobeNewswire

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

04 май 2023 11:09:06 Источник Nasdaq GlobeNewswire